Coherus Oncology, Inc.
CHRS
$1.20
$0.065.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.94M | 46.88M | 42.17M | 37.16M | 31.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.94M | 46.88M | 42.17M | 37.16M | 31.64M |
| Cost of Revenue | 15.82M | 14.98M | 13.81M | 12.52M | 11.53M |
| Gross Profit | 35.12M | 31.91M | 28.36M | 24.64M | 20.11M |
| SG&A Expenses | 87.90M | 92.98M | 95.90M | 104.50M | 109.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 204.93M | 214.03M | 218.61M | 215.70M | 214.80M |
| Operating Income | -154.00M | -167.15M | -176.43M | -178.54M | -183.16M |
| Income Before Tax | -161.15M | -172.66M | -183.12M | -182.87M | -185.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -161.15 | -172.66 | -183.12 | -182.87 | -185.95 |
| Earnings from Discontinued Operations | 29.01M | 358.93M | 351.15M | 337.84M | 365.70M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -132.13M | 186.27M | 168.02M | 154.97M | 179.75M |
| EBIT | -154.00M | -167.15M | -176.43M | -178.54M | -183.16M |
| EBITDA | -150.39M | -163.39M | -172.51M | -174.48M | -178.52M |
| EPS Basic | -1.03 | 1.67 | 1.46 | 1.33 | 1.54 |
| Normalized Basic EPS | -0.76 | -0.87 | -0.95 | -0.98 | -1.01 |
| EPS Diluted | -1.03 | 1.67 | 1.46 | 1.33 | 1.54 |
| Normalized Diluted EPS | -0.76 | -0.87 | -0.95 | -0.98 | -1.01 |
| Average Basic Shares Outstanding | 527.81M | 489.07M | 468.53M | 463.58M | 462.56M |
| Average Diluted Shares Outstanding | 527.81M | 489.07M | 468.53M | 463.58M | 462.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |